ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018

BURLINGTON, Mass.–(BUSINESS WIRE)–$ARQL #arql–ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and
Head of Research and Development, will present at The JMP Securities
Life Sciences Conference on June 21, 2018, at 10:30am EDT at the
St. Regis in New York.

The live webcast of the presentation will be available via the
“Investors & Media” section of ArQule’s website, www.arqule.com,
under “Events & Presentations.” A replay of the webcast will be
available shortly after the conclusion of the presentation.

About ArQule

ArQule is a biopharmaceutical company engaged in the research and
development of targeted therapeutics to treat cancers and rare diseases.
ArQule’s mission is to discover, develop and commercialize novel small
molecule drugs in areas of high unmet need that will dramatically extend
and improve the lives of our patients. Our clinical-stage pipeline
consists of five drug candidates, all of which are in targeted,
biomarker-defined patient populations, making ArQule a leader among
companies our size in precision medicine. ArQule’s pipeline includes:
ARQ 531, an orally bioavailable, potent and reversible inhibitor of both
wild type and C481S-mutant BTK, in Phase 1 for patients with B-cell
malignancies refractory to other therapeutic options; Miransertib (ARQ
092), a selective inhibitor of the AKT serine/threonine kinase, in a
phase 1/2 company-sponsored study for Overgrowth Diseases, in a Phase 1
study for ultra-rare Proteus syndrome conducted by the National
Institutes of Health (NIH), and in Phase 1b in combination with the
hormonal therapy, anastrozole, in patients with advanced endometrial
cancer; ARQ 751 a next generation AKT inhibitor, in Phase 1 for patients
with AKT1 and PI3K mutations; Derazantinib, a multi-kinase inhibitor
designed to preferentially inhibit the fibroblast growth factor receptor
(FGFR) family, in a registrational trial for iCCA; and ARQ 761, a
β-lapachone analog being evaluated as a promoter of NQO1-mediated
programmed cancer cell necrosis, in Phase 1/2 in multiple oncology
indications in partnership with the University of Texas Southwestern
Medical Center. ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors, leveraging
the Company’s proprietary library of compounds. You can follow us on Twitter
and LinkedIn.

Contacts

Corporate Contact:
ArQule, Inc.
Marc Schegerin, M.D.,
781-994-0440
Senior Vice President, Strategy, Communication and
Finance
marc@arqule.com
www.ArQule.com
or
Media
Contact:

LifeSci Public Relations
Allison Blum, Ph.D.,
646-627-8383
Allison@lifescipublicrelations.com